Results 211 to 220 of about 11,335 (243)

Ultrasound-Activated PROTAC Prodrugs Overcome Immunosuppression to Actuate Efficient Deep-Tissue Sono-Immunotherapy in Orthotopic Pancreatic Tumor Mouse Models.

Nano letters (Print)
The degradation of oncoproteins mediated by proteolysis-targeting chimera (PROTAC) has emerged as a potent strategy in cancer therapy. However, the clinical application of PROTACs is hampered by challenges such as poor water solubility and off-target ...
Ye Liu, Haiyang Wang, Mengchao Ding, Wang Yao, Kewei Wang, Ihsan Ullah, Emil Bulatov, Youyong Yuan   +7 more
semanticscholar   +1 more source

Methods to accelerate PROTAC drug discovery

Biochemical Journal
Proteolysis-targeting chimeras (PROTACs) represent a novel and promising modality for probing biological systems, elucidating pharmacological mechanisms, and identifying potential therapeutic leads. The field has made significant strides, as demonstrated
Jeyan Osman, Philip E. Thompson, M. Jörg, Martin J. Scanlon   +3 more
semanticscholar   +1 more source

MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition

Nature Communications
Proteolytic targeting chimera (PROTAC) technology is a protein-blocking technique and induces antitumor effects, with potential advantages. However, its effect is limited by insufficient distribution and accumulation in tumors.
Fan Tong, Yufan Wang, Yanyan Xu, Yang Zhou, Siqin He, Yufan Du, Wenqin Yang, Ting Lei, Yujun Song, Tao Gong, Huile Gao   +10 more
semanticscholar   +1 more source

A PROTAC Augmenter for Photo‐Driven Pyroptosis in Breast Cancer

Advances in Materials
Proteolysis targeting chimera (PROTAC) has recently emerged as a promising strategy for inducing post‐translational knockdown of target proteins in disease treatment.
Daipeng Huang, Yang Zou, Haiqiao Huang, Jikai Yin, Saran Long, Wen Sun, Jianjun Du, Jiangli Fan, Xiaoqiang Chen, Xiaojun Peng   +9 more
semanticscholar   +1 more source

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy.

Journal of the American Chemical Society
Proteolysis-targeting chimeras (PROTACs) show promise in tumor treatment. However, the E3 ligases VHL and CRBN, commonly used in PROTAC, are highly expressed in only a few tumors, thus limiting the application scope and efficacy of PROTAC drugs ...
Xucong Teng, Xuan Zhao, Yicong Dai, Xiangdong Zhang, Qiushuang Zhang, Yuncong Wu, Difei Hu, Jinghong Li   +7 more
semanticscholar   +1 more source

Co-delivery of PROTAC and siRNA via novel liposomes for the treatment of malignant tumors.

Journal of Colloid and Interface Science
Targeted elimination of damaged or overexpressed proteins within the tumor serves a pivotal role in regulating cellular function and restraining tumor cell growth.
Wenkai Zhang, Yi Jin, Jiayu Wang, Muge Gu, Yue Wang, Xiangqi Zhang, Yihui Zhang, Wei Yu, Yao Liu, Wei-En Yuan, Jing Su   +10 more
semanticscholar   +1 more source

Protecting with PROTAC

Nature Chemical Biology, 2022
openaire   +2 more sources

PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review.

International Journal of Biological Macromolecules
Proteolysis targeting chimera (PROTAC) technology is a promising new mode of targeted protein degradation with significant transformative implications for the clinical treatment of different diseases.
Chao Wang, Yujing Zhang, Wanpeng Yu, Jiazhen Xu, Dongming Xing   +4 more
semanticscholar   +1 more source

Benchmarking Methods for PROTAC Ternary Complex Structure Prediction

Journal of Chemical Information and Modeling
Proteolysis targeting chimeras (PROTACs) are bifunctional compounds that recruit an E3 ligase to a target protein to induce ubiquitination and degradation of the target.
E. Rovers, M. Schapira
semanticscholar   +1 more source

Developing bacterial PROTACs

Nature Reviews Drug Discovery, 2022
openaire   +2 more sources